COLLEGIUM PHARMACEUTICAL INC (COLL) Stock Fundamental Analysis

NASDAQ:COLL • US19459J1043

41.67 USD
-2.55 (-5.77%)
At close: Feb 27, 2026
41.67 USD
0 (0%)
After Hours: 2/27/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to COLL. COLL was compared to 193 industry peers in the Pharmaceuticals industry. COLL scores excellent on profitability, but there are some minor concerns on its financial health. COLL has a bad growth rate and is valued cheaply.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year COLL was profitable.
  • COLL had a positive operating cash flow in the past year.
  • In multiple years COLL reported negative net income over the last 5 years.
  • COLL had a positive operating cash flow in 4 of the past 5 years.
COLL Yearly Net Income VS EBIT VS OCF VS FCFCOLL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

1.2 Ratios

  • COLL's Return On Assets of 3.64% is amongst the best of the industry. COLL outperforms 84.97% of its industry peers.
  • Looking at the Return On Equity, with a value of 21.27%, COLL belongs to the top of the industry, outperforming 91.71% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 9.10%, COLL belongs to the best of the industry, outperforming 88.60% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for COLL is in line with the industry average of 12.93%.
Industry RankSector Rank
ROA 3.64%
ROE 21.27%
ROIC 9.1%
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
COLL Yearly ROA, ROE, ROICCOLL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

1.3 Margins

  • COLL has a better Profit Margin (7.72%) than 83.42% of its industry peers.
  • In the last couple of years the Profit Margin of COLL has declined.
  • COLL has a better Operating Margin (20.74%) than 88.08% of its industry peers.
  • In the last couple of years the Operating Margin of COLL has grown nicely.
  • COLL's Gross Margin of 57.22% is fine compared to the rest of the industry. COLL outperforms 69.43% of its industry peers.
  • In the last couple of years the Gross Margin of COLL has grown nicely.
Industry RankSector Rank
OM 20.74%
PM (TTM) 7.72%
GM 57.22%
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
COLL Yearly Profit, Operating, Gross MarginsCOLL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so COLL is still creating some value.
  • There is no outstanding debt for COLL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
COLL Yearly Shares OutstandingCOLL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
COLL Yearly Total Debt VS Total AssetsCOLL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • COLL has an Altman-Z score of 1.40. This is a bad value and indicates that COLL is not financially healthy and even has some risk of bankruptcy.
  • COLL has a Altman-Z score of 1.40. This is comparable to the rest of the industry: COLL outperforms 58.55% of its industry peers.
  • The Debt to FCF ratio of COLL is 2.79, which is a good value as it means it would take COLL, 2.79 years of fcf income to pay off all of its debts.
  • COLL has a Debt to FCF ratio of 2.79. This is amongst the best in the industry. COLL outperforms 92.23% of its industry peers.
  • A Debt/Equity ratio of 2.71 is on the high side and indicates that COLL has dependencies on debt financing.
  • With a Debt to Equity ratio value of 2.71, COLL is not doing good in the industry: 79.27% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.71
Debt/FCF 2.79
Altman-Z 1.4
ROIC/WACC1
WACC9.1%
COLL Yearly LT Debt VS Equity VS FCFCOLL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

2.3 Liquidity

  • A Current Ratio of 1.36 indicates that COLL should not have too much problems paying its short term obligations.
  • The Current ratio of COLL (1.36) is worse than 73.58% of its industry peers.
  • COLL has a Quick Ratio of 1.27. This is a normal value and indicates that COLL is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.27, COLL is doing worse than 68.39% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.36
Quick Ratio 1.27
COLL Yearly Current Assets VS Current LiabilitesCOLL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • COLL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.66%, which is quite good.
  • COLL shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 57.90% yearly.
EPS 1Y (TTM)15.66%
EPS 3Y137.06%
EPS 5Y57.9%
EPS Q2Q%15.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%12.92%

3.2 Future

  • Based on estimates for the next years, COLL will show a decrease in Earnings Per Share. The EPS will decrease by -1.74% on average per year.
  • The Revenue is expected to grow by 1.07% on average over the next years.
EPS Next Y8.61%
EPS Next 2Y-7.85%
EPS Next 3Y-14.45%
EPS Next 5Y-1.74%
Revenue Next Year3.54%
Revenue Next 2Y-3.97%
Revenue Next 3Y-4.36%
Revenue Next 5Y1.07%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
COLL Yearly Revenue VS EstimatesCOLL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
COLL Yearly EPS VS EstimatesCOLL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4 6 8

More info and screens

Find the best growth stocksShow best growing peers

9

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 5.59, which indicates a rather cheap valuation of COLL.
  • COLL's Price/Earnings ratio is rather cheap when compared to the industry. COLL is cheaper than 95.85% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.07. COLL is valued rather cheaply when compared to this.
  • A Price/Forward Earnings ratio of 5.14 indicates a rather cheap valuation of COLL.
  • Based on the Price/Forward Earnings ratio, COLL is valued cheaper than 95.34% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.05, COLL is valued rather cheaply.
Industry RankSector Rank
PE 5.59
Fwd PE 5.14
COLL Price Earnings VS Forward Price EarningsCOLL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 97.41% of the companies in the same industry are more expensive than COLL, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of COLL indicates a rather cheap valuation: COLL is cheaper than 97.41% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 4.55
EV/EBITDA 4.45
COLL Per share dataCOLL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

  • COLL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • COLL has a very decent profitability rating, which may justify a higher PE ratio.
  • COLL's earnings are expected to decrease with -14.45% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.65
PEG (5Y)0.1
EPS Next 2Y-7.85%
EPS Next 3Y-14.45%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for COLL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

COLLEGIUM PHARMACEUTICAL INC

NASDAQ:COLL (2/27/2026, 8:00:00 PM)

After market: 41.67 0 (0%)

41.67

-2.55 (-5.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners120.33%
Inst Owner Change1.04%
Ins Owners1.42%
Ins Owner Change2.29%
Market Cap1.32B
Revenue(TTM)N/A
Net Income(TTM)58.44M
Analysts81.67
Price Target54.74 (31.37%)
Short Float %15.42%
Short Ratio10.4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.9%
Min EPS beat(2)1.88%
Max EPS beat(2)7.92%
EPS beat(4)4
Avg EPS beat(4)6.15%
Min EPS beat(4)1.88%
Max EPS beat(4)12.85%
EPS beat(8)7
Avg EPS beat(8)12.99%
EPS beat(12)9
Avg EPS beat(12)-15.06%
EPS beat(16)10
Avg EPS beat(16)-21.97%
Revenue beat(2)2
Avg Revenue beat(2)5.22%
Min Revenue beat(2)1.9%
Max Revenue beat(2)8.53%
Revenue beat(4)3
Avg Revenue beat(4)2.75%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)8.53%
Revenue beat(8)4
Avg Revenue beat(8)0.8%
Revenue beat(12)6
Avg Revenue beat(12)0.28%
Revenue beat(16)8
Avg Revenue beat(16)-3.75%
PT rev (1m)0.94%
PT rev (3m)14.67%
EPS NQ rev (1m)0.07%
EPS NQ rev (3m)-3.91%
EPS NY rev (1m)0%
EPS NY rev (3m)-16.04%
Revenue NQ rev (1m)0.1%
Revenue NQ rev (3m)-0.35%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)3.94%
Valuation
Industry RankSector Rank
PE 5.59
Fwd PE 5.14
P/S 1.74
P/FCF 4.55
P/OCF 4.53
P/B 4.79
P/tB N/A
EV/EBITDA 4.45
EPS(TTM)7.46
EY17.9%
EPS(NY)8.1
Fwd EY19.44%
FCF(TTM)9.15
FCFY21.96%
OCF(TTM)9.2
OCFY22.09%
SpS23.95
BVpS8.69
TBVpS-18.86
PEG (NY)0.65
PEG (5Y)0.1
Graham Number38.2
Profitability
Industry RankSector Rank
ROA 3.64%
ROE 21.27%
ROCE 13.6%
ROIC 9.1%
ROICexc 12.09%
ROICexgc N/A
OM 20.74%
PM (TTM) 7.72%
GM 57.22%
FCFM 38.21%
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
ROICexc(3y)16.99%
ROICexc(5y)14.94%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)16.56%
ROCE(5y)13.94%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y15.58%
ROICexc growth 5YN/A
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
F-Score7
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 2.71
Debt/FCF 2.79
Debt/EBITDA 1.94
Cap/Depr 0.72%
Cap/Sales 0.21%
Interest Coverage 2.17
Cash Conversion 75.92%
Profit Quality 495.01%
Current Ratio 1.36
Quick Ratio 1.27
Altman-Z 1.4
F-Score7
WACC9.1%
ROIC/WACC1
Cap/Depr(3y)142.93%
Cap/Depr(5y)207.67%
Cap/Sales(3y)41.34%
Cap/Sales(5y)49.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.66%
EPS 3Y137.06%
EPS 5Y57.9%
EPS Q2Q%15.25%
EPS Next Y8.61%
EPS Next 2Y-7.85%
EPS Next 3Y-14.45%
EPS Next 5Y-1.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%12.92%
Revenue Next Year3.54%
Revenue Next 2Y-3.97%
Revenue Next 3Y-4.36%
Revenue Next 5Y1.07%
EBIT growth 1Y-18.86%
EBIT growth 3Y89.16%
EBIT growth 5YN/A
EBIT Next Year157.33%
EBIT Next 3Y30.45%
EBIT Next 5Y19.55%
FCF growth 1Y8.55%
FCF growth 3Y25.98%
FCF growth 5Y56.88%
OCF growth 1Y8.67%
OCF growth 3Y25.54%
OCF growth 5Y49.12%

COLLEGIUM PHARMACEUTICAL INC / COLL FAQ

What is the ChartMill fundamental rating of COLLEGIUM PHARMACEUTICAL INC (COLL) stock?

ChartMill assigns a fundamental rating of 5 / 10 to COLL.


What is the valuation status for COLL stock?

ChartMill assigns a valuation rating of 9 / 10 to COLLEGIUM PHARMACEUTICAL INC (COLL). This can be considered as Undervalued.


What is the profitability of COLL stock?

COLLEGIUM PHARMACEUTICAL INC (COLL) has a profitability rating of 7 / 10.


Can you provide the financial health for COLL stock?

The financial health rating of COLLEGIUM PHARMACEUTICAL INC (COLL) is 4 / 10.